PTRF Inhibitors
PTRF inhibitors constitute a diverse class of chemicals designed to modulate the function of PTRF, a protein intricately involved in cellular processes related to lipid raft formation and signaling. Simvastatin inhibits PTRF by targeting the mevalonate pathway, disrupting cholesterol biosynthesis and impacting PTRF-mediated signaling cascades. C75 inhibits PTRF by targeting fatty acid synthesis, disrupting lipid metabolism and influencing cellular processes dependent on lipid-rich microdomains. 2-Deoxyglucose (2-DG) inhibits PTRF through glycolysis inhibition, interfering with energy production and affecting cellular processes associated with PTRF-mediated signaling and lipid raft formation. Ro 31-8220 inhibits PTRF by targeting protein kinase C (PKC), modulating PTRF-related signaling pathways and influencing cellular processes dependent on PKC-mediated regulation. GW4869 inhibits PTRF through neutral sphingomyelinase (nSMase) inhibition, disrupting sphingolipid metabolism and impacting cellular processes associated with PTRF-mediated lipid raft formation and signaling.
Rapamycin inhibits PTRF by targeting the mTOR pathway, modulating PTRF-related signaling cascades and influencing cellular processes dependent on mTOR-mediated regulation. Bisindolylmaleimide I inhibits PTRF through PKC inhibition, modulating PTRF-related signaling pathways and affecting cellular processes dependent on PKC-mediated regulation. Betulinic Acid inhibits PTRF by modulating the Akt pathway, interfering with cellular processes associated with PTRF-mediated lipid raft formation and related signaling cascades. Imatinib Mesylate inhibits PTRF through the Abl kinase pathway, modulating PTRF-related signaling cascades and influencing cellular processes dependent on Abl kinase-mediated regulation. Terbinafine inhibits PTRF by targeting squalene epoxidase, disrupting cholesterol biosynthesis and impacting cellular processes associated with PTRF-mediated lipid raft formation and signaling. Collectively, these inhibitors provide a valuable toolkit for researchers to explore the dynamic regulation of PTRF in various cellular contexts, offering insights into lipid raft formation and related signaling pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin inhibits PTRF by modulating the mevalonate pathway. As a statin, simvastatin reduces cholesterol biosynthesis, impacting PTRF function by disrupting lipid raft formation and cellular processes associated with PTRF-mediated signaling. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $72.00 $206.00 $290.00 | 9 | |
C75 inhibits PTRF by targeting fatty acid synthesis. By inhibiting fatty acid synthase (FAS), C75 disrupts lipid metabolism, impacting PTRF-related processes dependent on lipid-rich microdomains and lipid-mediated signaling pathways. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose inhibits PTRF through glycolysis inhibition. By disrupting glucose metabolism, 2-DG interferes with energy production, affecting cellular processes associated with PTRF-mediated signaling and lipid raft formation. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro 31-8220 inhibits PTRF by targeting protein kinase C (PKC). As a PKC inhibitor, Ro 31-8220 modulates PTRF-related signaling pathways, influencing cellular processes dependent on PKC-mediated regulation of PTRF function. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 inhibits PTRF through neutral sphingomyelinase (nSMase) inhibition. By blocking nSMase activity, GW4869 disrupts sphingolipid metabolism, impacting cellular processes associated with PTRF-mediated lipid raft formation and signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits PTRF by targeting the mTOR pathway. As an mTOR inhibitor, rapamycin modulates PTRF-related signaling cascades, influencing cellular processes dependent on mTOR-mediated regulation of PTRF function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I inhibits PTRF through protein kinase C (PKC) inhibition. By targeting PKC, this compound modulates PTRF-related signaling pathways, affecting cellular processes dependent on PKC-mediated regulation of PTRF function. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic Acid inhibits PTRF by modulating the Akt pathway. By impacting Akt signaling, betulinic acid interferes with cellular processes associated with PTRF-mediated regulation, affecting lipid raft formation and related signaling cascades. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
Imatinib mesylate inhibits PTRF through the Abl kinase pathway. By targeting Abl kinase, imatinib mesylate modulates PTRF-related signaling cascades, influencing cellular processes dependent on Abl kinase-mediated regulation of PTRF function. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine inhibits PTRF by targeting squalene epoxidase. As a squalene epoxidase inhibitor, terbinafine disrupts cholesterol biosynthesis, impacting cellular processes associated with PTRF-mediated lipid raft formation and signaling. | ||||||